Showing results (381-390 of 458) with videos related to
Sort By:
Pageof 46
Journal for Immunotherapy of Cancer|September 27, 2022
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumorsJessica B Foster, Crystal Griffin, Jo Lynne Rokita, et al.The New England Journal of Medicine|October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaAlice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.Oncotarget|February 22, 2018
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology groupRisa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupAmi V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.Endocrine-Related Cancer|September 17, 2004
Malignant pheochromocytoma: current status and initiatives for future progressGraeme Eisenhofer, Stefan R Bornstein, Frederieke M Brouwers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Clare J Twist, Mary Lou Schmidt, Arlene Naranjo, et al.Cancer Research|December 18, 2004
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj, J Guillermo Paez, Frank S David, et al.Journal of Pediatric Surgery|September 24, 2024
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531Erin G Brown, E Stanton Adkins, Peter Mattei, et al.Science Advances|August 23, 2023
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in <i>MYCN</i>-amplified neuroblastomaHai-Feng Zhang, Alberto Delaidelli, Sumreen Javed, et al.Nature Communications|May 5, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastomaEsther R Berko, Gabriela M Witek, Smita Matkar, et al.Pageof 46